The FDA’s Expedited Programs and Clinical Development Times for Novel Therapeutics, 2012-2016

JAMA - Journal of the American Medical Association - United States
doi 10.1001/jama.2017.14896
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

American Medical Association (AMA)

Related search

Fast-Tracking Innovation: A Scorecard for the Fda’s Expedited Review Process

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Tracking Japan’s Development Assistance for Health, 2012–2016

Globalization and Health
Health PolicyPublic HealthOccupational HealthEnvironmental
2020English

Novel Clinical Therapeutics Targeting the Epithelial to Mesenchymal Transition

Clinical and Translational Medicine
MedicineMolecular Medicine
2014English

Targeting DNA Replication and Repair for the Development of Novel Therapeutics Against Tuberculosis

Frontiers in Molecular Biosciences
BiochemistryGeneticsMolecular Biology
2017English

Novel Targeted Therapeutics for MEN2

Endocrine-Related Cancer
Cancer ResearchEndocrinologyOncologyMetabolismDiabetes
2018English

Comparison of the Expedited Programs & Orphan Drug Designation in the Usa & Japan

Indian Research Journal of Pharmacy and Science
2018English

Novel Stroke Therapeutics: Unraveling Stroke Pathophysiology and Its Impact on Clinical Treatments

Neuron
Neuroscience
2015English

Clinical Pharmacology and Therapeutics.

Postgraduate Medical Journal
Medicine
1990English

Novel Therapeutics for Hemophilia and Other Bleeding Disorders

Blood
BiochemistryImmunologyCell BiologyHematology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy